Skip to main content
. 2021 Dec 10;161(5):1167–1179. doi: 10.1016/j.chest.2021.11.035

Figure 3.

Figure 3

A-C, Bar graphs showing changes in lung function during the PY. A, Without adjusting for ETI use and other variables, FEV1 percent predicted increased significantly from 69.3% in the PPY to 73.5% during the PY (P < .01). B, Determining the effect of triple combination cystic fibrosis transmembrane conductance regulator modulator therapy on lung function adjusting for year and other variables. Lung function improved by 4.4% because of therapy (P < .01). C, Adjusting for ETI use and other variables revealed no change in lung function from the PPY to PY (70.0 PPY vs 70.2 PY; P = .55). ETI = elexacaftor/tezacaftor/ivacaftor; PPY = prepandemic year; PY = pandemic year.